Detection

RA 11332
• Monkeypox shall be considered a notifiable disease (Mandatory
reporting of notifiable diseases and health events of public health
concern act)
Detection
• To rapidly identify cases, contacts, and clusters to provide rapid containment,
appropriate clinical care, and prevent further transmission.
• Samples of suspect or probable cases shall be coordinated with the
Epidemiology Bureau (EB) for referral to appropriate lab facility
• Bureau of Quarantine (BOQ) shall conduct symptom-based screening for
monkeypox for all incoming international travelers, especially those individuals
who came from countries with reported monkeypox cases.
• Symptom-based screening shall aim to capture the symptoms described in the
case definitions for patient under investigation or suspect cases of monkeypox.
• BOQ shall immediately coordinate suspected cases to the EB and designated
referral hospitals for further assessment, testing, and management.
Guidelines for Public Health Surveillance
• For humans
• All primary care providers, clinicians, public health authorities, points of entry, and
institutions/offices shall notify the DOH of any suspect, probable, or confirmed case
within 24 hours of detection
• Surveillance case definitions for monkeypox (Annex A1)
• Reporting of cases or contacts shall utilize the CIF (Annex B)
• Case investigation shall focus on
• Exposure investigation (back tracing) within 21 days prior to symptom onset
• Characterization of clinical presentation
• Tracing and profiling of identified contacts
• Contacts shall be quarantined and closely monitored at least a period of 21 days from
the last contact with a patient or their contaminated materials during the infectious
period
Guidelines for Public Health Surveillance
• For animals
• Shipments of rats and primates shall be strictly monitored by the Department
of Agriculture (DA), Department of Environment and Natural Resources
(DENR), and Bureau of Customs (BOC) for animals with monkeypox symptoms
Laboratory Confirmation
• Shall be done through the RT-PCR and/or whole-genome sequencing
of skin lesion samples and other samples, as may be included in
future policies
• Two adequate samples shall be collected
• Samples for WGS must be coordinated with EB through RESU for processing in
RITM or UP-PGC
• Second sample shall be sent to RITM for confirmatory testing through RT-PCR
• The RITM may opt to send out samples for PCR confirmation by its partner
facility in Australia
Reporting and Recording
• Cases reported to the RESU and EB using the CIF shall be recorded in
to a line list. The RESU and EB shall generate analysis and case
bulletins on a regular basis.